Wellbutrin XL

(bupropion hydrochloride)

Wellbutrin XL (bupropion hydrochloride); not controlled

Summary

Wellbutrin XL is an aminoketone antidepressant supplied as a once-daily extended-release tablet, approved for major depressive disorder and for prevention of seasonal affective disorder in adults. It has no pediatric indication at any age, so every use in a child or adolescent is off-label. Among antidepressants it is distinctive for no serotonergic action and no sexual dysfunction or weight gain, at the cost of a dose-related seizure risk. Not controlled; brand and generic.

Forms & Strengths

• Extended-release (XL) tablets: 150 mg, 300 mg, the only two XL strengths
• Sustained-release (SR) tablets: 100 mg, 150 mg, 200 mg, dosed twice daily
• Immediate-release tablets: 75 mg, 100 mg, dosed three times daily
• Separate NDAs: Forfivo XL 450 mg; Aplenzin (hydrobromide) 174 mg, 348 mg, 522 mg
• Combination products: dextromethorphan-bupropion (Auvelity); naltrexone-bupropion (Contrave)

Dosing

• Age: adults only. No pediatric indication at any age and no pediatric ADHD indication at any age; any use in a young person is off-label.
• Onset: 1 to 2 weeks for early effect; 4 to 6 weeks for full response
• Duration: continuous with once-daily dosing; bupropion half-life 21 hours, hydroxybupropion about 20 hours
• Release Profile: once-daily matrix tablet, bioequivalent over 24 hours to immediate-release 100 mg three times daily
• Initial Dose: 150 mg once daily, for both approved indications
• Titration:
  • Major depressive disorder: may increase to 300 mg once daily after 4 days
  • Seasonal affective disorder: may increase to 300 mg once daily after 1 week
  • Increase gradually; abrupt escalation raises the seizure risk
• Max Dose: 300 mg/day. The 450 mg ceiling belongs to Forfivo XL, a different product
• Considerations: Moderate to severe hepatic impairment caps the dose at 150 mg every other day; mild impairment or GFR under 90 mL/min needs a reduced dose or frequency.

Pharmacology

• Mechanism: norepinephrine-dopamine reuptake inhibitor; no serotonin reuptake or monoamine oxidase inhibition
• Metabolism: CYP2B6 to hydroxybupropion, the principal active metabolite. Renal excretion of metabolites means impairment causes accumulation
• Class Positioning: chosen for the absent serotonergic action: no sexual dysfunction, appetite suppression rather than weight gain. Approved non-stimulant alternatives are Strattera and Qelbree

Indications

• Major Depressive Disorder (ICD-10: F32.x, F33.x): adults only
• Seasonal Affective Disorder, prevention (ICD-10: F33.x seasonal pattern): adults only. Start in autumn, continue through winter
• No pediatric indication at any age, and specifically no pediatric ADHD indication

Off-Label Uses

• ADHD in children and adolescents (ICD-10: F90.x): limited data. Second-line where a stimulant is not tolerated and depression coexists.
  • The label carries no ADHD indication and no ADHD trial.
  • AHRQ found medication improves ADHD symptoms overall but graded no bupropion-specific pediatric evidence. (AHRQ 2024)
  • Weigh the seizure risk against the two approved non-stimulants first.
• Pediatric major depressive disorder (ICD-10: F32.x, F33.x): insufficient; the adult indication does not extend downward.
• Adolescent smoking or vaping cessation (ICD-10: F17.2x): insufficient. The label's neuropsychiatric warning applies at any age.
• Any use in a patient with an eating disorder (ICD-10: F50.x): contraindicated, not merely unsupported.

Contraindications & Warnings

• Boxed Warning: SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants increased suicidal thinking and behaviour in children, adolescents and young adults. Monitor for worsening and emergent suicidality, including in off-label pediatric use.
• Contraindicated:
  • Seizure disorder.
  • Current or prior bulimia or anorexia nervosa; absolute, and easily missed in an adolescent.
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptics; withdrawal lowers the seizure threshold.
  • Concomitant MAOI, or use within 14 days of stopping one; initiation on linezolid or intravenous methylene blue.
  • Known hypersensitivity to bupropion or any other ingredient.
• Use with caution:
  • Conditions lowering the seizure threshold: severe head injury, arteriovenous malformation, CNS tumour or infection, stroke, hypoglycemia, hyponatremia, hypoxia.
  • Never co-prescribe two bupropion products, and see Drug Interactions for other threshold-lowering drugs.
  • Insulin- or oral-hypoglycemic-treated diabetes, and anorectic drugs; both predispose to seizure.
  • Pre-existing hypertension, because bupropion raises blood pressure.
  • Bipolar disorder or risk factors: activation of mania or hypomania.
  • Untreated anatomically narrow angles: angle-closure glaucoma.
  • Renal impairment below GFR 90 mL/min; active metabolites accumulate.
• Screen before starting:
  • Seizure and head injury history, and any eating disorder. Ask the adolescent alone; bulimia is rarely volunteered.
  • Current alcohol, benzodiazepine or antiepileptic use, and any plan to stop.
  • Personal and family history of bipolar disorder or mania.
  • Blood pressure, measured before initiation.
  • Medication list for MAOIs, other bupropion products, seizure-threshold drugs.
  • Hepatic and renal function where impairment is plausible; both change the dose.

Drug Interactions

• MAOIs (phenelzine, tranylcypromine, linezolid, intravenous methylene blue): hypertensive reactions. Contraindicated; allow 14 days in either direction.
• CYP2D6 substrates (venlafaxine, nortriptyline, paroxetine, fluoxetine, risperidone, metoprolol, flecainide, atomoxetine): bupropion raises exposure. Reduce the substrate dose.
• CYP2B6 inducers (ritonavir, efavirenz, carbamazepine, phenytoin): exposure falls. An increase may be needed, never above 300 mg/day.
• CYP2B6 inhibitors (ticlopidine, clopidogrel): bupropion exposure rises 38% to 85%. Adjust on clinical response.
• Seizure-threshold drugs (other bupropion products, antipsychotics, tricyclics, theophylline, corticosteroids, tramadol): additive risk. Avoid, or hold at 150 mg/day.
• Levodopa and amantadine: CNS toxicity. Use lower doses.
• Urine drug screens: false-positive for amphetamines. Confirm before treating a positive as diversion of a prescribed amphetamine (Adderall).

Administration

• Give once daily in the morning to limit early insomnia.
• Swallow whole; breaking the matrix converts a daily dose into an immediate-release bolus.
• An intact tablet shell in the stool is expected, not a missed dose.
• Never escalate faster than the label allows: 4 days to 300 mg for depression, 1 week for SAD.
• Switching from immediate-release or SR: same total daily dose as one XL dose; confirm the product.
• For seasonal affective disorder, start in autumn, continue through winter, taper in early spring.
• Do not stop abruptly from 300 mg. See Discontinuation & Taper.

Side Effects

• Common (at least 5% and twice placebo): dry mouth, nausea, insomnia, dizziness, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, anorexia, rash
• Serious:
  • Suicidal thoughts and behaviour: the boxed warning.
  • Seizure, dose-related: about 0.1% up to 300 mg/day sustained-release, about 0.4% at 300 to 450 mg/day immediate-release. Discontinue permanently.
  • Serious neuropsychiatric events during smoking cessation: depression, mania, psychosis, hallucinations, aggression, agitation, panic.
  • Hypertension.
  • Activation of mania or hypomania: stop and reassess the diagnosis.
  • Angle-closure glaucoma: sudden eye pain, redness or visual change needs same-day ophthalmology.
  • Hypersensitivity, including serum-sickness-like reactions.

Monitoring & Labs

• Suicidality: weekly for 4 weeks, every visit through 3 months, every dose change, then each routine visit.
• Blood pressure: baseline, 4 weeks, every dose change, then every 3 months.
• Seizure risk review: at every dose increase and at least every 6 months. Re-ask about threshold-lowering drugs, alcohol or benzodiazepine use, and disordered eating.
• Weight and appetite: baseline and every 3 months. Unexplained loss prompts a direct question about disordered eating.
• Psychiatric: ask about mania, agitation, anxiety and insomnia each visit during titration, then every 3 months.
• Renal and hepatic function: no routine schedule; recheck when circumstances change.
• Urine drug screens: confirm any positive amphetamine result rather than acting on the immunoassay.

Discontinuation & Taper

• Taper before stopping: from 300 mg once daily, decrease to 150 mg once daily before discontinuation.
• Discontinue permanently and never restart if a seizure occurs.
• Stop and seek review for serious neuropsychiatric symptoms.
• Drug holidays are not appropriate; the effect depends on continuous exposure.
• For seasonal affective disorder, taper in early spring rather than continuing year-round.

Pregnancy & Lactation

• Pregnancy: first-trimester studies show no increased risk of congenital malformations overall.
  • Registry cardiovascular malformation rate 1.3% against a roughly 1% background; cardiac findings are inconsistent.
  • Background risk is 2 to 4% for birth defects, 15 to 20% for miscarriage; weigh continuation against relapse.
• Lactation: maternal doses up to 300 mg daily give low milk levels. Case reports describe possible seizure in partially breastfed 6-month-olds; prefer another agent for a newborn. (LactMed 2026)
• Exposure Registry: National Pregnancy Registry for Antidepressants, 1-844-405-6185, womensmentalhealth.org

Counseling Points

• Counsel the family on:

  • This being an adult medication used off-label, with no pediatric dose ladder.
  • Never taking two bupropion products; the drug is sold under several brands.
  • Swallowing the tablet whole; an empty shell in the stool is normal.
  • Insomnia and jitteriness in the first weeks, fixed by morning dosing.
  • Telling any clinician ordering a urine drug test, because it reads as amphetamine.
  • Stepping the dose down before stopping rather than stopping outright.

• Advise them to call for:

  • Any seizure, including a staring spell or single whole-body jerk; stop and call the same day.
  • New or worsening talk of self-harm, or a sudden mood change.
  • A burst of high energy, reduced need for sleep, or racing speech.
  • Hearing or seeing things that are not there, or new suspiciousness.
  • Sudden eye pain, redness or blurred vision.
  • Rash, hives, facial or tongue swelling, or joint pains with fever.
  • Any plan to stop alcohol, a benzodiazepine, or a seizure medicine abruptly.

References

1. DailyMed. Wellbutrin XL (bupropion hydrochloride extended-release tablets) prescribing information. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21
2. LactMed. Bupropion. Drugs and Lactation Database, National Institute of Child Health and Human Development. 2026. https://www.ncbi.nlm.nih.gov/books/NBK501184/
3. AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK603001/
4. FDA. National Drug Code Directory, openFDA. Queried by generic name bupropion. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22bupropion%22&limit=1000